Analysis of Gene Polymorphism CYP2C19 in the Lebanese Population Who Reside in Colombia

Ahmad, Mostapha; Quiroz, Elkin Navarro; Margarita, García Moreno Angélica; Anillo, Margarita Rosa Ríos; Redondo, C.; Ponce, Cecilia Fernandez

doi:10.5539/gjhs.v10n7p36

Cited by 3 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the qualitative part included 10 studies, four case series, and 6 observational studies. These ten studies reported the frequency of CYP2C19 polymorphisms among Arabs [24][25][26][27].…”

Section: Included Studiesmentioning

confidence: 99%

The efficacy of clopidogrel in preventing recurrent cardiovascular events among Arab population carrying different CYP2C19 mutations: systematic review and meta-analysis

Alkattan

Radwan

Mahmoud

et al. 2022

Egypt J Med Hum Genet

View full text Add to dashboard Cite

Background The prevalence and the role of CYP2C19 gene mutations concerning recurrent Cardiovascular Events (CVEs) among patients treated with clopidogrel is still controversial especially among Arab people. Therefore, this review aimed to determine the frequency of CYP2C19 polymorphic alleles among the Arab population and to investigate the efficacy of clopidogrel as an antiplatelet drug among those carrying different variants of this gene. Methodology Two authors independently searched in PubMed, Google Scholar, and EMBASE databases at any year for studies related to the role of CYP2C19 gene on the prognosis of patients with CVEs treated with clopidogrel. The review included Arab people who were genotyped to determine the frequency of CYP2C19 genotypes and alleles (the qualitative part). Concerning the quantitative part (meta-analysis), only patients who previously had CVEs and using clopidogrel as secondary prophylaxis had been included. The Newcastle Ottawa Scale for non-randomizes Studies was utilized to consider the risk of bias among included studies. We analyzed the data using odds ratio at 95% confidence interval and the quality of evidence of each outcome measure was judged using GRADE approach. Results The current study revealed that 4% of Arabs reported in the included studies are homozygous, and 25% are heterozygous for the CYP2C19*2 allele. While 3% and 18.5% of them are homozygous and heterozygous of CYP2C19*17 alleles, respectively. A significant increased risk of recurrent CVEs by about threefold was associated with CYP2C19*2 or CYP2C19*3 allele carriers (OR = 3.32, CI = 1.94–5.67, and OR = 3.53, CI = 1.17–10.63, respectively). However, no significant increased risk among carriers of CYP2C19*17 mutation (OR = 0.80, (CI = 0.44–1.44) was documented. Conclusion The present study revealed that Arabs carrying CYP2C19*2 and CYP2C19*3 alleles could be at increased risk of decreasing the antiplatelet efficacy of clopidogrel and an alternative drug should be prescribed for those patients to avoid recurrent CVEs. However, few available studies were included in the quantitative part of the analysis and further studies with large sample size are recommended to confirm our results.

show abstract

Section: Included Studiesmentioning

confidence: 99%

The efficacy of clopidogrel in preventing recurrent cardiovascular events among Arab population carrying different CYP2C19 mutations: systematic review and meta-analysis

Alkattan

Radwan

Mahmoud

et al. 2022

Egypt J Med Hum Genet

View full text Add to dashboard Cite

show abstract

The role of CYP2C19 gene polymorphisms on antiplatelet activity of clopidogrel among Arabs: systematic review and meta-analysis

Alkattan

Radwan

Mahmoud

et al. 2022

Preprint

View full text Add to dashboard Cite

The aim of this study was to predict the preventive effect of clopidogrel against recurrent cardiovascular events (CVEs) among the Arab population carrying different CYP2C19 gene mutations and to determine the frequency of polymorphic alleles and genotypes of CYP2C19 gene among them. The review included all the available studies that reported data related to the CYP2C19 gene polymorphisms among Arab populations. The review included Arab CVDs patients who are categorized into carriers (cases) and non-carriers (controls) of CYP2C19 alleles and use clopidogrel as secondary prophylaxis. The patients who had recurrent CVEs or had high on treatment platelet reactivity (HTPR) while using clopidogrel treatment were described as (events). The results showed a significant increased risk of recurrent CVDs events by about three folds was associated with carriers of CYP2C19*2 and CYP2C19*3 mutations compared to non-carriers (OR= 3.32, CI=1.94-5.67, and OR=3.53, CI=1.17-10.63 respectively). However, no significant difference was recorded between both studied groups regarding the presence of CYP2C19*17 mutation (OR=0.80, (CI=0.44-1.44). The results also revealed that 59 (4.16%) of Arabs carrying two CYP2C19*2 alleles (homozygous), and 356 (25.12%) have one CYP2C19*2 allele and one CYP2C19*1 allele (heterozygous). Moreover, 42 (2.96%) were carrying two CYP2C19*17 alleles (homozygous), and 262 (18.49%) were carrying one CYP2C19*17 allele and one wild-type allele of CYP2C19 gene (heterozygous). The most common CYP2C19 genotypes reported among Arabs was the wild-type *1/*1, which 49.26% of them were having the homozygous form of CYP2C19*1 allele. The frequency of CYP2C19*1 allele was 71.07%, followed by CYP2C19*2 allele (16.73%) and CYP2C19*17 (12.21%), respectively. Regarding the CYP2C19*3 allele, it was detected rarely among Arabs (<1%) compared to CYP2C19*1, *2, and *17 alleles. The present study revealed that Arabs carrying CYP2C19*2 and CYP2C19*3 alleles may not respond to clopidogrel and may put those patients at risk of recurrent CVEs. Carriers of CYP2C19*17 allele, on the other hand, did not showed a significant role either in increase or decrease the antiplatelet efficacy of clopidogrel. The CYP2C19 genotypes including *1/*1, *1/*2, *1/*17, *2/*2, and *17/*17 are commonly distributed among the Arabs.

show abstract

The CYP2C19 genotypes and its effect on clopidogrel as an anti-platelet drug among the Arab population

et al. 2021

View full text Add to dashboard Cite

Analysis of Gene Polymorphism CYP2C19 in the Lebanese Population Who Reside in Colombia

Cited by 3 publications

References 9 publications

The efficacy of clopidogrel in preventing recurrent cardiovascular events among Arab population carrying different CYP2C19 mutations: systematic review and meta-analysis

The efficacy of clopidogrel in preventing recurrent cardiovascular events among Arab population carrying different CYP2C19 mutations: systematic review and meta-analysis

The role of CYP2C19 gene polymorphisms on antiplatelet activity of clopidogrel among Arabs: systematic review and meta-analysis

The CYP2C19 genotypes and its effect on clopidogrel as an anti-platelet drug among the Arab population

Contact Info

Product

Resources

About